Myelodysplastic-Myeloproliferative Diseases  >>  Jakafi (ruxolitinib)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jakafi (ruxolitinib) / Incyte
NCT01164163: INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Completed
1
49
US
ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study
Children's Oncology Group, National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
10/14
 

Download Options